SLP Corporate Timeline

Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit, Dispensary of Hope

Expanding access to high-quality medication for people in need Read More

Read More

Grace Fraczkiewicz Celebrates 20 Years of Service

In January 2020, Grace Fraczkiewicz celebrated her 20 years of service with Simulations Plus. Read About her Journey

Read More

Robert Fraczkiewicz Celebrates 20 Years of Service

In August of 2018, Robert Fraczkiewicz celebrated his 20 years of service with Simulations Plus. Read About his Journey

Read More

Hosts The Inaugural 2021 MIDD+ Scientific Conference

Simulations Plus hosts the Inaugural 2021 MIDD+ Scientific Conference with over 50 Model-Informed Drug Development Sessions. Read More

Read More

Simulations Plus Raised About $115 Million Underwritten Public Offering of Common Stock

Simulations Plus announced underwritten public offering of 2,090,909 shares of its common stock to the public at $55.00 per share. Learn More

Read More

Lixoft becomes a subsidiary of Simulations Plus

Lixoft becomes a wholly owned subsidiary of Simulations Plus on April, 2020. Lixoft is design software solutions based on scientific breakthroughs to reduce the cost and increase the success rate of new drug development. Learn More

Read More

Releases ADMET Predictor® Version 10.0 (APX™)

Simulations Plus released version 10.0 of its flagship machine learning modeling platform, ADMET Predictor®, The new release is marketed as APX™ on September 2020. Read More

Read More

Simulations Plus Names Shawn O’Connor as CEO

Shawn M. O’Connor appointed as Chief Executive Officer(CEO) effective from June 26, 2018. Learn More

Read More

S+pKa Model Wins SAMPL6 pKa Challenge

Predictions of ionization constants performed by the S+pKa method implemented in ADMET Predictor™ software wins SAMPL6 pKa challenge on February 2018. Learn More

Read More

DILIsym Services, Inc. Becomes a Subsidiary of Simulations Plus

DILIsym becomes a wholly owned subsidiary of Simulations Plus. DILIsym is the global leader in the simulation of drug-induced liver injury (“DILI”). Learn More

Read More